Get the Stockscreener App
1.055
3.43%
0.035
Lucid Diagnostics Inc stock is traded at $1.055, with a volume of 1.10M.
It is up +3.43% in the last 24 hours and down -12.81% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.02
Open:
$1.015
24h Volume:
1.10M
Relative Volume:
0.95
Market Cap:
$145.26M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-0.9769
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
-1.40%
1M Performance:
-12.81%
6M Performance:
-20.68%
1Y Performance:
+5.61%
1-Day Range:
$1.00
$1.07
1-Week Range:
$1.00
$1.10
52-Week Range:
$0.7501
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.055 | 133.72M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
GenomeWeb Names Lucid Diagnostics (Nasdaq: LUCD) 2025 Best Places to Work Honoree - Stock Titan
Ranking Lucid Diagnostics Inc. among high performing stocks via tools2025 Top Decliners & AI Powered Trade Plan Recommendations - newser.com
Lucid Diagnostics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Developing predictive dashboards with Lucid Diagnostics Inc. dataBear Alert & Fast Gain Swing Alerts - newser.com
Lucid Diagnostics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Live market analysis of Lucid Diagnostics Inc.Weekly Market Report & Long Hold Capital Preservation Tips - newser.com
Why retail investors favor Lucid Diagnostics Inc. stockAnalyst Downgrade & Stock Portfolio Risk Control - newser.com
Is Lucid Diagnostics Inc. stock oversold or undervaluedMarket Growth Report & Pattern Based Trade Signal System - newser.com
Measuring Lucid Diagnostics Inc.’s beta against major indices - newser.com
Lucid Diagnostics’ Earnings Call: Strategic Wins Amid Challenges - MSN
Combining machine learning predictions for Lucid Diagnostics Inc.2025 Major Catalysts & Daily Volume Surge Trade Alerts - newser.com
Why Lucid Diagnostics Inc. stock is considered a top pickJuly 2025 Momentum & Community Consensus Picks - newser.com
Is Lucid Diagnostics Inc. meeting your algorithmic filter criteriaEarnings Performance Report & Weekly Momentum Stock Picks - newser.com
Earnings call transcript: Lucid Diagnostics Q3 2025 reports revenue growth and strategic advancements - Investing.com Nigeria
Lucid Diagnostics Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:LUCD) 2025-11-14 - Seeking Alpha
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - Eastern Progress
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lucid Diagnostics Gains Medicare Support for EsoGuard - MSN
Is Lucid Diagnostics Inc. stock ready for a breakoutJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
PAVmed Inc (PAVM) Q3 2025 Earnings Call Highlights: Strategic Pa - GuruFocus
PAVmed Inc (PAVM) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... - Yahoo Finance
Lucid Diagnostics to Participate in the Canaccord Genuity MedTec - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2025 Earnings Call Transcript - Insider Monkey
Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q3 2025 Earnings Conference - 富途牛牛
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results - MarketScreener
Needham reiterates Buy rating on Lucid Diagnostics stock amid EsoGuard growth - Investing.com Nigeria
Needham Reiterates Lucid Diagnostics (LUCD) Buy Recommendation - Nasdaq
Lucid Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Australia
Lucid Diagnostics Inc (LUCD) Q3 2025 Earnings Call Highlights: Strategic Growth Plans Amidst ... By GuruFocus - Investing.com Canada
Lucid Diagnostics Reports Q3 2025 Financial Results - TipRanks
Lucid Diagnostics Q3 2025 Earnings Call Transcript - MarketBeat
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):